RAP resulted higher than in VR patients. Future investigation on local IL-18 protein production, its autocrine-paracrine effect and its correlation with plasmatic IL-18 level could give more information on the relationship between IL-18 and coronary artery disease.
Interleukin-IS (IL-18) is a member of the interleukin-I (IL-I) family of cytokines originally described as an interferon gamma inducing factor (I). Once secreted, the cytokine displays a proinflammatory activity by enhancing T cell and natural killer cell maturation, as well as the production of cytokines, chemokines and cell adhesion molecules (I). The cytokine is produced constitutively in many different cell types, including macrophages/ monocytes, endothelial cells, smooth muscle cells, dendritic cells, as well as in cardiomyocytes (2, 3) . In addition, the observation that circulating level of IL-18 is elevated in human obesity and that weight loss is associated with proportional reduction of its level suggested that a likely site for IL-18 production may be adipose tissue (4) .
Different reports suggested that inflammation plays a crucial role in the pathogenesis not only of atherosclerosis (5) (6) (7) but also in aortic stenosis (8, 9) . Among different pro-inflammatory molecules, IL-18 immunoreactivity was found both in atherosclerotic lesions as well as in stenotic aortic valves (10) . Moreover, increased level ofIL-18 has been observed following myocardial infarction, heart failure and stroke (11) . The cytokine is also beginning to be considered as an important modulator of myocardial remodeling by promoting myocardial fibrosis through direct actions on the cardiac fibroblasts (II).
Due to the link between obesity, inflammation and cardiovascular diseases, we aimed to measure IL-18 circulating level in patients with different degrees of adiposity undergoing open-heart surgery both for elective coronary artery bypass grafting (CABG) surgery or for valve replacement (VR).
Epicardial adipose tissue (EAT) is a fat depot which is closely apposed on the myocardium and several lines of evidence suggested that it is not only a lipid-storing depot, but also an active endocrine organ able to secrete inflammatory cytokines and chemokines (12) which promote cardiac remodelling (13, 14) . For these reasons we evaluated whether EAT depot could also be a potential source of IL-18 and whether IL-18 receptor 1 (IL-18 RI) and IL-18 receptor accessory protein (IL-18-RAP) are also expressed by the tissue.
MATERIALS AND METHODS

Study population
Between August 2010 and April 2011, 23 patients who underwent elective CABG surgery and 9 patients who received open-heart surgery for VR were enrolled. VR patients did not show any sign of coronary artery disease in the pre-operative coronary angiographic examination. A group of 20 normal-weight, age-matched, healthy subjects was also included in the study as control group. Patients with recent acute myocardial infarction, malignant disease, prior major abdominal surgery, renal failure and more than 3% variation in body weight in the previous 3 months were excluded. Patients were measured for height, weight, waist and hip circumferences; BMI and waist/hip ratio (WHR) were calculated.
Patients gave informed consent to the examination protocol, conducted in accordance with the Declaration of Helsinki, as revised in 2000.
Blood collection
Blood samples were collected after an overnight fasting into pyrogen-free tubes with ethylendiaminetetraacetic acid as anticoagulant. Plasma samples were separated after centrifugation at 1000 g for 15 min and were stored at -20°C until analysis. Fasting glucose, insulin, total cholesterol, HDL-and LDL-cholesterol, triglycerides and other biochemical parameters were assayed in the IRCCS Policlinico San Donato central laboratory as also previously reported (15) . The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated using the following equation: HOMA-IR = fasting insulin [J..lU/mL] x fasting glucose [mmol/L] / 22.5.
EAT collection
EAT biopsy samples were harvested adjacent to the proximal right coronary artery prior to initiation of cardiopulmonary bypass pumping. Samples were snap frozen in liquid nitrogen and stored at -80°C until RNA extraction.
EAT depot quantification
All patients were examined by echocardiography using an M-mode color-Doppler VSF (Vingmed-System Five; General Electric, Horten, Norway) with a 2.5-to 3.5-MHz transducer probe. EATthickness was measured on the free wall of the right ventricle from both parasternal long-and short-axis views and appears as an non-homogeneous echo-free space, as previously reported (16) . We chose to measure EAT thickness on the right ventricle for two reasons: (1) this point is recognized as the greatest absolute EAT thickness (17) ; and (2) parasternal long-and shortaxis views allow the most accurate measurement of EAT on the right ventricle with optimal cursor beam orientation in each view (16) .
Immunoassays
Circulating level of IL-18 was assayed by enzymelinked immunosorbent assay (ELISA) according to the manufacturer's procedure (MBL International Woburn, MA). Reported maximum intra-and interassay coefficients of variation were 10.8% and 10.06%, respectively. The minimum detection limit estimated was 12.5 pg/mL.
The Evidence Investigator and Biochip High-sensitivity Array Technology (Randox Laboratories, Crumlin, Northern Ireland, UK) were used for the simultaneous detection of IL-6 and IL-8 on a single plasma sample. The experimental procedures were performed following the manufacturer's instructions. The technology uses a biochip, a 9 mm-solid substrate supporting an array of discrete test regions, with immobilized antigen-specific antibodies. Briefly, 200~L of assay diluent and 100~L of calibrators/samples were added to the biochip well and after 1hour ofincubation at 37°C and 370 rpm the biochips were washed. Then, 300~L of a conjugated antibody was added to the biochip well and after incubation for 1 h at 37°C and 370 rpm the biochips were washed and the signal reagent (luminol and peroxide in a ratio of 1:1) was added. The chemiluminescent signal output generated was detected using digital imaging technology and resulted directly proportional to the concentration of the analytes in the samples. Sensitivity, measuring range and intraand inter-assay coefficients of variation were: 0.12 pg/ mL, 0-400 pg/rnL, 11.9% and 8.4% for IL-6; 0.36 pg/mL, 0-1450 pg/mL, 9.4% and 11.1% forIL-8, respectively.
RNA extraction and gene expression analysis
Total RNA was extracted from tissue with the RNeasy Lipid Tissue Kit according to the manufacturer's procedure (Qiagen, Hilden, Germany). RNA concentration was quantified by NanoDrop 2000 (ThermoScientific, Wilmington, Germany). RNA integrity was assessed using the Agilent RNA 6000 Nano kit and the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Gene expression analysis was performed by one color microarray platform (Agilent). We evaluated IL-18, IL-18 Rl and IL-18-RAP by a global gene expression analysis performed by Agilent microarray which has 41000 human genes and transcripts with one 60-mer oligonucleotide probe representing each sequence. Seventy-five selected probes are replicated 10 times to allow intra-array reproducibility measurement.
Statistical analysis
Data are expressed as mean ±SD. The normality ofdata distribution was assessed by the Kolmogorov-Smirnoff test. Comparison between groups was performed using Student's two-tailed t-test. Correlation between IL-18 and other parameters was examined by Pearson's correlation coefficient. All statistical analyses were performed using STATISTIX7.0 (Analytical Software, Tallahassee, FL). A P value < 0.05 was considered significant.
RESULTS
Baseline characteristics and biochemicalparameters
Some demographic and anthropometric characteristics of patients and healthy control subjects are shown in Tables I and II, respectively. No significant difference in the measurements of weight, height, BMI, waist and hip circumferences was observed between CABG and VR patients. WHR resulted higher in the VR than in the CABG group (p < 0.05). No difference was observed in echocardiographic EAT thickness among the two groups. Patients currently smoking, with hypertension and with history of dyslipidemia were significantly prevalent in the CABG group. The number of patients affected by type II diabetes mellitus was also higher in CABG patients. The percentages of antiplatelets, statins, angiotensinogen-converting enzyme inhibitors/angiotensin receptor blockers and oral glucose-lowering drugs were significantly higher in the CABG than in the VR group.
Biochemical profiles of CABG and VR patients are shown in Table III . Relative to glucose profiles, HbA Ic level resulted higher in CABG vs VR patients (p < 0.05). Relative to lipid profile, higher total cholesterol and LDL levels were observed in VR vs CABG subjects (p < 0.01 for both), whereas HDL resulted lower in CABG vs VR patients (p < 0.05). We also observed increased ALT level in CABG vs VR group (p < 0.04). . lA) . On the contrary, no statistically significant difference was observed in IL-18 level between the two groups of cardiovascular patients (CABG vs VR, P = 0.35) ( Fig. lA ). According to their adiposity index, 22.6% of the patients had a BMI between 18.5 and 24.9 (normal weight), 61.3% had a BMI between 25 and 29.9 (overweight) and 16.1% had a BMI of30 or greater (obese). After classification ofthe subjects according to BMI, in each group IL-18 level resulted higher than in healthy controls (normal weight vs controls: 267.40±80.90 pg/mL vs l24.75±15.03 pg/mL, p < 0.01; overweight vs controls: 3l7.40±152.57 vs l24.75±15.03 pg/mL, p < 0.001; obese vs controls: 302.80±115.56 pg/mL vs l24.75±15.03 pg/mL, p < 0.05) ( Fig. lB) . No statistically significant difference was observed between the three subgroups (normal weight, over weight and obese) of cardiovascular patients (Fig. lB) .
1L-18 circulating level
According to the different adipose tissue distribution, patients classified utilizing the waist circumference measure as a risk factor for cardiometabolic complications (18) . In a first analysis, patients were divided into two groups utilizing the waist circumference cut off value of?: 94 and then IL-18 level was evaluated in these two groups (group one comprised patients with a waist circumference ?: 94 em and group two patients 305.9l±24.49 vs 325.95±27.69 pg/mL, p = 0.87; waist circumference cut-off'> 102 em: 363.6l±57.48 vs 292.57±20.95 pg/mL, p = 0.17) (Fig. 2) . IL-18 level was also evaluated after classification of cardiovascular patients according to the median echocardiographic EAT thickness value (8 mm) . Also in this case, no difference in circulating IL-18 level was observed between the two groups (EAT thickness and echocardiographic EAT thickness (r = 0.800, P = 0.333).
Comparison of/L-18, /L-18 R1 and /L-18-RAP gene expression levels in EAT depot between CABG and VRpatients
A great increase in the expression of all the evaluated genes was observed in CABG vs VR patients (Fig. 3) . In particular, a 77-fold increase (FI) was observed for IL-18 gene, a 31 FI for IL-18 Rl and a 242 FI for IL-18-RAP.
No correlation was observed between IL-18 circulating level and IL-18 gene expression in EAT depot (r = 0.694, p = 0.542).
/L-6 circulating level
Quantification of circulating IL-6 protein indicated that patients had higher IL-6 levels than controls (6.21±1.45 pg/mL vs 1.23±0.17 pg/mL, mean ± SD, P < 0.001). After subdivision in CABG and VR patients, in both groups IL-6 resulted higher than in controls (CABG vs controls: 7.l7±1.8l pg/ mL vs 1.23±0.17 pg/mL, p < 0.001; VR vs controls: 2.75±0.33 pg/mL vs 1.23±0.17 pg/mL, p < 0.001). IL-6 level was also higher in CABG compared to VR patients (p < 0.05).
/L-8 circulating level
Quantification of circulating IL-8 protein indicated no statistical significant difference between controls and CABG (2.7l±1.82 pg/mL vs 2.98±0.25 pg/mL, p = 0.73), and between controls and VR patients (2.78±1.l8 pg/mL vs 2.98±0.25 pg/mL, p = 0.93). No difference has also been observed between CABG and VR patients(p = 0.78).
DISCUSSION
In this study we found that patients undergoing two different kinds of open heart surgery, CABG or VR, have increased circulating IL-18levels compared to healthy control subjects, independently of their adiposity status and adipose tissue distribution. Moreover, we demonstrated, for the first time, that EAT depot is a potential source of IL-18 and that, in particular, IL-18 gene expression is higher in EAT depot isolated from CABG than VR patients.
In previous reports, plasma IL-18 level has been identified as an independent predictor of CAD both in healthy men and in men with CAD risk factors (19) . Moreover, increased IL-18 expression has been reported in human unstable atherosclerotic plaque, suggesting that IL-18 may play an important role in plaque destabilization (5) . In light of these observations, it was not surprising to observe significantly elevated plasma IL-18 levels in CABG patients which presented extensive CAD. On the other hand, in our study we also observed increased IL-18 circulating levels in patients with no signs of CAD. This means that, although IL-18 received great attention for its association with atherogenesis and plaque instability, it may also play a role in other non-CAD pathology patients receiving open-heart surgery, such as valve replacement, supporting a recent report indicating that IL-18 is up-regulated in non-rheumatic aortic stenosis (10) . Therefore, IL-18 circulating protein may reflect a general inflammatory status of the heart more than appearing as a factor selectively correlated with a specific heart pathology. Furthermore, the observation that these two groups ofpatients presented the same circulating levels of IL-18 does not exclude the possibility that local IL-18 levels may be different. Previous studies indicated that IL-18 may be produced by adipose tissue, even if its secretion was approximately 1000 times lower than that of other interleukins, like IL-6 and IL-8 (20, 21) . These observations may therefore suggest that adipose tissue-derived IL-18 is of minor or no importance to circulating IL-18 level, but it is possible that the adipose tissue-derived-IL-18 exerts autocrine or paracrine pro-inflammatory effects within the adipose tissue or tissues closely apposed. For this reason, we focused our attention on EAT, a visceral fat depot located along the large coronary arteries and on the surface of the ventricles and the apex of the heart, able to secrete different adipokines and cytokines (12, 22) . Since EAT depot is not separated by a fascia from the underlying tissue, it can locally affect the heart and coronary arteries through vasocrine and paracrine secretion of pro-inflammatory mediators. Thus, we evaluated whether a different local production of IL-18 by EAT depot may be observed among the two groups of patients. In CABG patients, we observed not only an increased production of IL-18 but also of its receptor Rl and of IL-18-RAP, an accessory subunit of the heterodimeric receptor for IL-18 which enhances the IL-18 binding activity ofIL-18 Rl and is required for the activation of NF-kappaB and MAPK8 (JNK) in response to IL-18 (23) . One possible limitation of our study may be the fact that we performed only a gene expression study and we did not directly quantify the amount of protein produced by EAT depot. Since isolation of EAT during surgery is a delicate and difficult procedure and the amount of tissue isolated is often poor, particularly in the case ofnormal weight patients, and not enough to perform both RNA and protein expression analysis, we first decided to carry out gene expression study. Our data seem to suggest that in CABG patients a major autocrine-paracrine effect of IL-18 may exist. This means that IL-18 may directly affect heart and blood vessels of the heart and exert a pro-inflammatory effect within the EAT depot by promoting the release of other cytokines, as already previously indicated (24) . Thus, although no differences have been observed in the circulating levels of IL-18 between the two groups of patients, a strong and important difference was observed at local level, at least in terms of gene expression. Also the observation that IL-18 circulating level did not correlate with IL-18 gene expression at EAT level seems to suggest that circulating IL-18 does not reflect the local cytokine synthesis, thus reinforcing our hypothesis of the existence of a different local production of the cytokine in the two groups of patients. The evaluation of IL-18 protein produced by EAT depot and also the quantification of IL-18 at intracoronary level, i.e. as was previously carried out for adrenomedullin (25) , in future patients will allow us to confirm our preliminary RNA expression study. In our study we also evaluated echocardiographic EAT thickness in the two groups of patients. A growing number of studies indicated that echocardiographic EATthickness strongly and independently reflects the intra-abdominal visceral fat (26) and intra-myocardial lipid content (27) . In addition, it is also significantly and independently related to the metabolic syndrome and other traditional cardiovascular risk factors (26) and is associated with the presence and severity of CAD (28) . In our study we did not observe any difference in echocardiographic EAT thickness among the two groups of patients. This observation could be explained by considering that patients had also similar waist circumference. In fact, this anthropometric parameter, as well as EAT thickness, reflects the amount of visceral fat content, and the observation that both measures were not different suggested similar visceral fat level in the two groups of patients.
We have also observed that most of the patients included in our study were under pharmacological treatments to normalize altered glucose and/or lipid profile. In particular, the use of cholesterol-lowering drugs was higher in CABG vs VR patients and this could explain why in VR patients cholesterol levels appeared to be higher than in CABG patients. Focusing on statins, recent reports have suggested that some ofthese, in addition to their lipid-lowering action, also possess an anti-inflammatory effect and, in particular, they are able to reduce IL-18 circulating level (29, 30) . On the contrary, other reports suggested no association between statins and inflammatory cytokines (31) . Considering that about 87% of the patients in the CABG group were under statin therapy compared to about 22% in the VR group, the possibility that IL-18 level in CABG patients appears similar to those observed in the VR group due to the reducing effect of the drug therapy may exist. For this reason we also monitored other pro-inflammatory cytokines, such as IL-6 and IL-8. Whereas IL-8 levels were the same in the two groups of patients as well as in controls, the observation that IL-6 levels were higher in CABG respect to VR patients prompted us to consider a lack of drug effect overall.
In conclusion, our data thus indicate that in CABG patients, EAT depot may be a potential source ofIL-18. Future investigation on local IL-18 protein production and its correlation with plasmatic IL-18 level and echocardiographic EAT thickness could give more information on the relationship between IL-18 and CAD.
